SYDNEY, AUSTRALIA--(Marketwire - Sep 21, 2012) - Prima BioMed Ltd ( ASX : PRR ) ( NASDAQ : PBMD ) (Prima, the Company) announces that its CEO Matthew Lehman will present a corporate update at BIOX; Noble Financial Capital Markets' Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus (USA) on September 24-25, 2012.
Following the event, a high-definition video webcast of Prima's presentation and a copy of the presentation materials will be available on the Company's web site.
About Prima BioMed
Prima BioMed is a globally active biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.